FinnGen is proud to welcome Alnylam Pharmaceuticals as its newest industry partner. As the 15th pharmaceutical company to join the public-private partnership, Alnylam brings world-leading expertise in RNA interference (RNAi) therapeutics to the consortium, further enriching the scientific and translational potential of the FinnGen study.